Sanofi CEO: Cap drug prices

The new Sanofi CEO has some radical idea. In his first interview since taking the helm at Sanofi-Aventis, CEO Gérard Le Fur (photo) told the Financial Times that drug makers ought to cut prices and rely on volume for profits. Skyrocketing costs for new drugs "cannot continue," he said. He himself expects to focus on emerging markets for growth--and those markets can't support the kind of prices paid in more developed nations.

The free-ranging interview also touched on possible cost-cutting at Sanofi, and on potential acquisitions, perhaps in Japan. He plans to look at biotech acquisitions and at licensing deals, too, boosting the latter to 25 to 30 percent of the company's pipeline. And he predicts that Sanofi's vaccine sales will double to 20 percent of group revenue from 10 percent today.

- read the interview from the Financial Times

Related Articles:
Sanofi underscores pipeline advances, setbacks. Report
What's Warren Buffett buying now? Report
Pfizer-Sanofi match not made in heaven? Report
Sanofi stock up on Pfizer buyout talk. Report

Read more on: Sanofi-Aventis

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.